BioCentury
ARTICLE | Product Development

With second approval of year, Blueprint readies to put partner Genentech into play 

September 5, 2020 3:22 AM UTC

Two months after partnering with Roche in one of the year’s biggest deals, Blueprint has its second FDA approval of the year with pralsetinib in NSCLC. The biotech believes the efficacy and safety profile of its RET fusion inhibitor will set it apart from first-in-class Retevmo, the lead asset in Lilly’s $8 billion deal to acquire Loxo.

FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDAQ:BPMC) late Friday for metastatic RET fusion-positive non-small cell lung cancer  detected by an FDA-approved test. It is Blueprint’s second FDA approval in less than a year, following Ayvakit avapritinib’s January approval in gastrointestinal stromal tumors. ...